Mr. Abhai Pandey

CET Group 7 focuses on contentious IP issues including but not limited to IP opposition (both pre and post grant), revocation, appeal, infringement action, amicable settlement of disputes including via alternate dispute resolution as well as substantive and procedural aspects related thereto.

On behalf of FICPI, Group 7 also endeavours to keep a close watch on all crucial national and international developments on IP enforcement landscape including on custom actions, anti-counterfeit issues, reciprocal judgements, professional privilege, transfer of right etc and keep its membership abreast of such developments from time to time. Group 7 also aims to create a go to list of certified arbitrators and/or mediators within FICPI.

CET Group 5 is dedicated to following, reporting and providing substantive comments and opinions on emerging issues relating to the patenting and regulatory affairs in the Biotechnology and Pharmaceutical fields. 

In addition, CET 5 is closely following developments related to genetic resources and developing requirements for notice on their country of origin.  Prominent issues CET 5 addresses regarding patenting in these technological fields include subject matter eligibility, and in particular, the patentability of chemical/biological inventions developed using machines, computer implementation and/or artificial intelligence.  CET 5 supports FICPI in its mission to be an international leader promoting patent protection in the biotechnology and pharmaceutical arts.